Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
16 patents granted to the 4 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Cellectar Biosciences, Inc.’s names, not what it holds today.
Patents granted
16
16 utility, 1976 to Dec 31, 2025
Granted in 2025
2
in the last year the record reads
Applications published
22
since 2001, to Dec 31, 2025
Names they are printed under
4
its own name, a former name, a subsidiary
By yearGrantedApplications published
'05'07'08'11'13'14'15'16'17'18'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals2
Measurement1
Organic fine chemistry1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name4 counted
CELLECTAR BIOSCIENCES, INC. its own name
US, as the owner printed on each patent
1 publishedNovelos Therapeutics, Incorporated a former name
US, as the owner printed on each patent
5 publishedCellectar Biosciences, Inc. its own name
named as the applicant on its applications, in US
10 publishedCellectar, Inc. a subsidiary
named as the applicant on its applications, in US
6 published
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|
| Dec 23, 2025 | 12,503,479 | Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapy | Organic fine chemistry | CELLECTAR BIOSCIENCES, INC. |
| Dec 16, 2025 | 12,496,346 | Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapy | Pharmaceuticals | CELLECTAR BIOSCIENCES, INC. |
| Oct 11, 2022 | 11,467,159 | Luminescent phospholipid analogs for the identification and isolation of circulating tumor cells | Measurement | CELLECTAR BIOSCIENCES, INC. |
| Sep 13, 2022 | 11,439,709 | Phospholipid ether analogs as cancer-targeting drug vehicles | Pharmaceuticals | CELLECTAR BIOSCIENCES, INC. |
| Mar 27, 2018 | 9,925,269 | Phospholipid ether analogs as cancer-targeting drug vehicles | Pharmaceuticals | CELLECTAR BIOSCIENCES, INC. |
| Apr 11, 2017 | 9,616,140 | Fluorescent phospholipid ether compounds, compositions, and methods of use | Pharmaceuticals | CELLECTAR BIOSCIENCES, INC. |
| Feb 28, 2017 | 9,579,406 | Phospholipid ether analogs as agents for detecting and locating cancer, and methods thereof | Pharmaceuticals | CELLECTAR BIOSCIENCES, INC. |
| Jan 24, 2017 | 9,550,002 | Phospholipid analogs as diapeutic agents and methods thereof | Pharmaceuticals | CELLECTAR BIOSCIENCES, INC. |
| Nov 1, 2016 | 9,480,754 | Phospholipid ether analogs as cancer-targeting drug vehicles | Pharmaceuticals | CELLECTAR BIOSCIENCES, INC. |
| May 24, 2016 | 9,345,718 | Phospholipid ether analogs as cancer-targeting drug vehicles | Pharmaceuticals | CELLECTAR BIOSCIENCES, INC. |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Oct 3, 2024 | 2024/0325545 | Phospholipid-Flavagline Conjugates and Methods of Using the Same for Targeted Cancer Therapy | Pharmaceuticals | Cellectar Biosciences, Inc. · patent 12,496,346 granted from it |
| Apr 25, 2024 | 2024/0131204 | Fractionated Dosing of a Phospholipid Ether Analog for the Treatment of Cancer | Pharmaceuticals | Cellectar Biosciences, Inc. |
| Mar 2, 2023 | 2023/0066517 | Phospholipid Ether Conjugates as Cancer-Targeting Drug Vehicles | Organic fine chemistry | Cellectar Biosciences, Inc. |
| Jun 3, 2021 | 2021/0163513 | Phospholipid-Flavagline Conjugates and Methods of Using the Same for Targeted Cancer Therapy | Organic fine chemistry | CELLECTAR BIOSCIENCES, INC. · patent 12,503,479 granted from it |
| Apr 15, 2021 | 2021/0106700 | Fractionated Dosing of a Phospholipid Ether Analog for the Treatment of Cancer | Pharmaceuticals | Cellectar Biosciences, Inc. |
| Nov 22, 2018 | 2018/0333498 | Phospholipid Ether Analogs as Cancer-Targeting Drug Vehicles | Pharmaceuticals | Cellectar Biosciences, Inc. · patent 11,439,709 granted from it |
| Dec 14, 2017 | 2017/0356914 | PHOSPHOLIPID ETHER ANALOGS FOR THE IDENTIFICATION AND ISOLATION OF CIRCULATING TUMOR CELLS | Measurement | Cellectar Biosciences, Inc. · patent 11,467,159 granted from it |
| Aug 11, 2016 | 2016/0228588 | ETHER AND ALKYL PHOSPHOLIPID COMPOUNDS FOR TREATING CANCER AND IMAGING AND DETECTION OF CANCER | Pharmaceuticals | Cellectar Biosciences, Inc. · patent 10,004,818 granted from it |
| Aug 11, 2016 | 2016/0228564 | Phospholipid Ether Analogs as Cancer-Targeting Drug Vehicles | Pharmaceuticals | Cellectar Biosciences, Inc. · patent 9,480,754 granted from it |
| May 19, 2016 | 2016/0136290 | Phospholipid Ether Analogs as Cancer-Targeting Drug Vehicles | Pharmaceuticals | Cellectar Biosciences, Inc. · patent 9,925,269 granted from it |
What it applied for, 2024 to 2025: Pharmaceuticals 2.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.